Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dako and Bristol-Myers Squibb have entered into a partnership agreement to develop pharmacodiagnostic tests.
Subscribe to our email newsletter
The pharmacodiagnostic tests are intended to identify the patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb.
Dakos CEO Lars Holmkvist said the partnership agreements simply underpin the company’s mission to deliver the highest standards and accurate diagnoses — ultimately to the benefit of patients.